Literature DB >> 19944970

Clinical applications of a peptide-based vaccine for glioblastoma.

Charles W Kanaly1, Dale Ding, Amy B Heimberger, John H Sampson.   

Abstract

Glioblastoma multiforme is a malignant, relentless brain cancer with no known cure, and standard therapies leave significant room for the development of better, more effective treatments. Immunotherapy is a promising approach to the treatment of solid tumors that directs the patient's own immune system to destroy tumor cells. The most successful immunologically based cancer therapy to date involves the passive administration of monoclonal antibodies, but significant antitumor responses have also been generated with active vaccination strategies and cell-transfer therapies. This article summarizes the important components of the immune system, discusses the specific difficulty of immunologic privilege in the central nervous system, and reviews treatment approaches that are being attempted, with an emphasis on active immunotherapy using peptide vaccines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19944970      PMCID: PMC2824535          DOI: 10.1016/j.nec.2009.09.001

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  120 in total

1.  Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.

Authors:  R W Rand; R J Kreitman; N Patronas; F Varricchio; I Pastan; R K Puri
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

2.  Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.

Authors:  M R Zalutsky; R P Moseley; H B Coakham; R E Coleman; D D Bigner
Journal:  Cancer Res       Date:  1989-05-15       Impact factor: 12.701

3.  High-flow microinfusion: tissue penetration and pharmacodynamics.

Authors:  P F Morrison; D W Laske; H Bobo; E H Oldfield; R L Dedrick
Journal:  Am J Physiol       Date:  1994-01

4.  Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

Authors:  B C Pestalozzi; D Zahrieh; K N Price; S B Holmberg; J Lindtner; J Collins; D Crivellari; M F Fey; E Murray; O Pagani; E Simoncini; M Castiglione-Gertsch; R D Gelber; A S Coates; A Goldhirsch
Journal:  Ann Oncol       Date:  2006-04-07       Impact factor: 32.976

Review 5.  Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

Authors:  Giorgio Parmiani; Chiara Castelli; Piero Dalerba; Roberta Mortarini; Licia Rivoltini; Francesco M Marincola; Andrea Anichini
Journal:  J Natl Cancer Inst       Date:  2002-06-05       Impact factor: 13.506

6.  Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.

Authors:  J N Cormier; M L Salgaller; T Prevette; K C Barracchini; L Rivoltini; N P Restifo; S A Rosenberg; F M Marincola
Journal:  Cancer J Sci Am       Date:  1997 Jan-Feb

7.  Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.

Authors:  Masanori Noguchi; Kazuhiko Kobayashi; Norie Suetsugu; Katsurou Tomiyasu; Shigetaka Suekane; Akira Yamada; Kyogo Itoh; Shinshi Noda
Journal:  Prostate       Date:  2003-09-15       Impact factor: 4.104

8.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

Authors:  S A Rosenberg; J C Yang; S L Topalian; D J Schwartzentruber; J S Weber; D R Parkinson; C A Seipp; J H Einhorn; D E White
Journal:  JAMA       Date:  1994 Mar 23-30       Impact factor: 56.272

9.  Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

Authors:  S A Rosenberg; J C Yang; D E White; S M Steinberg
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

10.  Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.

Authors:  Robert J Schmittling; Gary E Archer; Duane A Mitchell; Amy Heimberger; Charles Pegram; James E Herndon; Henry S Friedman; Darell D Bigner; John H Sampson
Journal:  J Immunol Methods       Date:  2008-09-04       Impact factor: 2.303

View more
  12 in total

Review 1.  Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.

Authors:  T E Taylor; F B Furnari; W K Cavenee
Journal:  Curr Cancer Drug Targets       Date:  2012-03       Impact factor: 3.428

2.  Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation.

Authors:  Tom B Davidson; Alexander Lee; Melody Hsu; Shaina Sedighim; Joey Orpilla; Janet Treger; Max Mastall; Saskia Roesch; Carmen Rapp; Mildred Galvez; Aaron Mochizuki; Joseph Antonios; Alejandro Garcia; Nikesh Kotecha; Nicholas Bayless; David Nathanson; Anthony Wang; Richard Everson; William H Yong; Timothy F Cloughesy; Linda M Liau; Christel Herold-Mende; Robert M Prins
Journal:  Clin Cancer Res       Date:  2018-11-29       Impact factor: 12.531

Review 3.  Immunotherapy for the treatment of glioblastoma.

Authors:  Alissa A Thomas; Marc S Ernstoff; Camilo E Fadul
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

4.  Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.

Authors:  Joseph P Antonios; Horacio Soto; Richard G Everson; Diana Moughon; Joey R Orpilla; Namjo P Shin; Shaina Sedighim; Janet Treger; Sylvia Odesa; Alexander Tucker; William H Yong; Gang Li; Timothy F Cloughesy; Linda M Liau; Robert M Prins
Journal:  Neuro Oncol       Date:  2017-06-01       Impact factor: 12.300

5.  Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.

Authors:  Zachary Barnard; Hiroaki Wakimoto; Cecile Zaupa; Anoop P Patel; Jacquelyn Klehm; Robert L Martuza; Samuel D Rabkin; William T Curry
Journal:  Neurosurgery       Date:  2012-09       Impact factor: 4.654

6.  PD-1 blockade enhances the vaccination-induced immune response in glioma.

Authors:  Joseph P Antonios; Horacio Soto; Richard G Everson; Joey Orpilla; Diana Moughon; Namjo Shin; Shaina Sedighim; William H Yong; Gang Li; Timothy F Cloughesy; Linda M Liau; Robert M Prins
Journal:  JCI Insight       Date:  2016-07-07

7.  T-cell epitope finding on EPHA2 for further glioma vaccine development: An immunomics study.

Authors:  Viroj Wiwanitkit
Journal:  J Pediatr Neurosci       Date:  2011-01

Review 8.  Cellular-based immunotherapies for patients with glioblastoma multiforme.

Authors:  Xun Xu; Florian Stockhammer; Michael Schmitt
Journal:  Clin Dev Immunol       Date:  2012-02-28

9.  Monocyte galactose/N-acetylgalactosamine-specific C-type lectin receptor stimulant immunotherapy of an experimental glioma. Part 1: stimulatory effects on blood monocytes and monocyte-derived cells of the brain.

Authors:  Sergiy V Kushchayev; Tejas Sankar; Laura L Eggink; Yevgeniya S Kushchayeva; Philip C Wiener; J Kenneth Hoober; Jennifer Eschbacher; Ruolan Liu; Fu-Dong Shi; Mohammed G Abdelwahab; Adrienne C Scheck; Mark C Preul
Journal:  Cancer Manag Res       Date:  2012-09-17       Impact factor: 3.989

Review 10.  Glioblastoma multiforme: State of the art and future therapeutics.

Authors:  Taylor A Wilson; Matthias A Karajannis; David H Harter
Journal:  Surg Neurol Int       Date:  2014-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.